Zoetis stock

ZTS · NYSE · USD

Compare Zoetis
$83.48Change from previous close: −1.08%Absolute change: −$0.91

Close · November 17, 2026

Price history

−29.56% over the period

1 year: from $118.80 (November 17, 2025) to $83.69 (November 17, 2026), −29.56%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$83.69
October 30, 2026$79.72
September 30, 2026$69.83
August 31, 2026$77.10
July 31, 2026$77.29
June 30, 2026$71.86
May 29, 2026$77.69
April 30, 2026$114.97
March 31, 2026$118.21
February 27, 2026$131.10
January 30, 2026$124.82
December 31, 2025$125.82
November 28, 2025$128.18
November 17, 2025$118.80

At a glance

  • The company

    Discover, develop, manufacture and commercialize medicines, vaccines, diagnostics and precision animal health solutions for companion and livestock animals

  • Latest results

    Quarter to September 30, 2026 · EPS $1.75 (estimate $1.51)

TickerLandia's take on Zoetis

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$68.77
52-wk high$132.49

−36.99% from the 52-week high

Analysts · 16 analysts

Average target$89.69+7.44% vs. price

Buy 6 · Hold 10 · Sell 0 · Buy

TickerLandia Fingerprint: Zoetis

Compared with similar companies: very high profitability.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Zoetis is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Zoetis's P/E today is 13.9, below the median of its last 10 fiscal years (35.8; between 20.9 and 57.1 from 2016 to 2025). Zoetis's P/E (trailing 12 months): 14.1, −49% against the median of a group of 9 similar companies (27.6).

P/E compared with its history

Compared with 9 similar companies

Zoetis's metrics compared with similar companies
MetricZoetisPosition in the groupBand
P/E (trailing 12 months)14.1Low
Forward P/E13.1Low
Operating margin37.9%High
ROE57.6%High
Debt/equity2.80High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Zoetis. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$2.39B

Latest quarter · Q3 2026

Net income

$591M

Latest quarter · Q3 2026

Quarterly net margin

24.7%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$33.92B
P/E
14.1
EPS
$5.94
Volume
3.35M
Daily trading
€341.63M
Dividend yield
2.54%
Last ex-dividend on October 30, 2026

How Zoetis is changing

All results
  • Revenue grew 7.2% a year on average over the last 5 years

  • Operating margin rose from 36.3% to 38.3%

  • Free cash flow equal to 83% of net income

Returns

Zoetis returns with dividends

$1,000 invested in Zoetis 5 years ago, on November 17, 2021, would be worth $401 today with dividends reinvested: −59.88% in total, −16.70% per year. On price alone it would be $377 (−62.28%).

PeriodZoetisS&P 500$1,000 becomes
1 month+5.15%−3.17%$1,051
6 months+12.48%+0.11%$1,125
Year to date−33.49%+8.34%$665
1 year−27.98%+11.15%$720
3 years−49.91%+64.30%$501
5 years−59.88%+58.18%$401
10 years+86.49%+239.10%$1,865

Over the last 6 months it has done better than 45% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Zoetis: technical analysis

Zoetis shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 66.2% below its all-time closing high ($247.03, December 29, 2021).

Trend
No clear trend
RSI (14 sessions)
57
Between 30 and 70
vs 200-session average
−8.34%

Support and resistance

Price areas where Zoetis has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$123.87+48.38%2 touches, last on April 20, 2026
  2. Resistance$119.50+43.15%2 touches, last on February 12, 2026
  3. Resistance$115.42+38.26%2 touches, last on December 9, 2025
  4. Last price$83.48
  5. Support$82.54−1.13%3 touches, last on October 22, 2026
  6. Support$78.07−6.47%6 touches, last on November 6, 2026
  7. Support$73.47−12.00%2 touches, last on July 23, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.61
Volatility (60 sessions, annualised)
35.0%
Largest fall in the last year
−47.29%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Zoetis: seasonality

Average monthly price change over 14 years

−1.5%Jan+1.8%Feb−2.0%Mar+1.2%Apr+0.2%May+0.7%Jun+3.5%Jul+1.1%Aug−1.4%Sep+0.2%Oct+3.9%Nov+1.6%Dec

Over the last 14 years, the strongest month for Zoetis has been November: +3.88% on average, positive in 9 years out of 13. The weakest has been March: −1.96% on average, positive in 6 years out of 14.

Show chart data
MonthAverageMedianPositive years
January−1.50%−0.70%6 of 13
February+1.80%+0.91%8 of 13
March−1.96%−0.24%6 of 14
April+1.25%+0.56%7 of 14
May+0.19%+1.14%9 of 14
June+0.72%+0.36%9 of 14
July+3.51%+2.92%12 of 14
August+1.13%+1.27%10 of 14
September−1.38%−0.19%7 of 14
October+0.23%+0.33%8 of 14
November+3.88%+2.70%9 of 13
December+1.63%+2.61%7 of 13

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Zoetis and its competitors

Based in Parsippany, New Jersey, Zoetis was founded in 1952 and works in animal health, covering the discovery, development, manufacture and sale of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision animal health solutions. Its products are aimed mainly at companion animals such as dogs, cats and horses, and at livestock including cattle, swine, poultry, fish and sheep, and are marketed to veterinarians, livestock producers and pet owners.

Headquarters
Parsippany, United States
Employees
14,500
Founded
1952
Chief executive
Kristin Peck
Zoetis and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
ZoetisZTS$33.92B37.9%14.1+12.48%
United TherapeuticsUTHR$25.04B39.4%22.2+2.73%
ViatrisVTRS$23.58B——+24.09%
Teva Pharmaceutical IndustriesTEVA$49.67B19.8%99.0+24.29%
Neurocrine BiosciencesNBIX$16.73B26.6%24.5+4.73%
Hims & Hers HealthHIMS$4.13B-6.4%—−29.94%

Same industry or related industries, similar size. Compare Zoetis with its competitors · Full profile